IN BRIEF: ImmuPharma rises on FDA feedback for neurological disease

ImmuPharma PLC - London-based drug discovery and development company - Gets positive support and ...

Alliance News 18 May, 2023 | 11:12AM
Email Form Facebook Twitter LinkedIn RSS

ImmuPharma PLC - London-based drug discovery and development company - Gets positive support and guidance from the US Food & Drug Administration after a pre-investigational new drug meeting, which confirms the route for a Phase 2/3 adaptive clinical study of P140 in chronic idiopathic demyelinating polyneuropathy. Says the feedback recognises that P140 is suitable to be studied in another disease indication, in addition to systemic lupus erythematosus.

Says the CIDP market is expected to reach global sales of USD2.7 billion by 2029. CIDP is a rare neurological disease with high medical need.

Chief Executive Officer Tim McCarthy says: "We are delighted to have received this positive support and guidance from the FDA on our pre-IND application for CIDP. As we now move forward to a full IND application this program remains on track to commence its Phase 2/3 adaptive clinical trial in H2 2023. Furthermore, as our P140 technology platform provides the basis for both our Lupus and CIDP programs, we look forward to also commencing the Lupus Phase 2/3 clinical trial in H2 2023 ".

Current stock price: 3.39 pence each, up 10% on Thursday around noon in London

12-month change: down 43%

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
ImmuPharma PLC 2.23 GBX -2.70 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures